IT1262896B
(it)
*
|
1992-03-06 |
1996-07-22 |
|
Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
|
US5849301A
(en)
*
|
1993-09-22 |
1998-12-15 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
|
CA2171942C
(fr)
*
|
1993-09-22 |
2010-12-14 |
Andrew Lees |
Methode d'activation de carbohydrate soluble, utilisant de nouveaux reactifs de cyanylation pour l'obtention de constructions immunogenes
|
NZ304715A
(en)
*
|
1995-03-22 |
1999-07-29 |
Jackson H M Found Military Med |
Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
|
NZ306316A
(en)
*
|
1995-04-17 |
2001-06-29 |
Smithkline Beecham Biolog S |
use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
|
US20030157129A1
(en)
*
|
1995-06-23 |
2003-08-21 |
Smithkline Beecham Biologicals S.A. |
Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
|
US6447777B1
(en)
*
|
1996-03-29 |
2002-09-10 |
David S. Terman |
Polymerized staphylococcal protein a for treatment of diseases
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
WO1997049425A1
(fr)
|
1996-06-25 |
1997-12-31 |
Stichting Instituut Voor Dierhouderij En Diergezondheid |
Vaccins comprenant des antigenes fixes sur leurs supports par des liaisons labiles
|
US6248334B1
(en)
*
|
1997-01-08 |
2001-06-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
EP0977588B1
(fr)
*
|
1997-04-24 |
2004-10-06 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Couplage de proteines non modifiees a des polysaccharides derives d'haloacyle ou de dihaloacyle pour la preparation de vaccins renfermant des proteines-polysaccharides
|
US5929049A
(en)
|
1997-08-08 |
1999-07-27 |
Dade Behring Marburg Gmbh |
Polysaccharide conjugates of biomolecules
|
US6284250B1
(en)
*
|
1998-02-05 |
2001-09-04 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
|
AU3005499A
(en)
*
|
1998-03-16 |
1999-10-11 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties
|
WO1999052548A2
(fr)
*
|
1998-04-10 |
1999-10-21 |
Andrew Lees |
Vaccins conjugues pour la prevention contre les caries dentaires
|
GB9808932D0
(en)
*
|
1998-04-27 |
1998-06-24 |
Chiron Spa |
Polyepitope carrier protein
|
US6432679B1
(en)
|
1998-06-12 |
2002-08-13 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
|
AU767047B2
(en)
*
|
1998-07-20 |
2003-10-30 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Vaccines against (escherichia coli) O157 infection
|
US6858211B1
(en)
*
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
US6585973B1
(en)
|
1998-10-29 |
2003-07-01 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Method for preparing solid phase conjugated vaccine
|
US6797275B1
(en)
*
|
1998-12-04 |
2004-09-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
|
EP1880735A3
(fr)
|
1999-03-19 |
2008-03-12 |
GlaxoSmithKline Biologicals S.A. |
Vaccin
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
DK1296715T4
(en)
|
2000-06-29 |
2016-03-07 |
Smithkline Beecham Biolog |
Multivalent vaccine composition.
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB0115176D0
(en)
*
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US7534442B2
(en)
*
|
2001-08-21 |
2009-05-19 |
The Brigham And Women's Hospital, Inc. |
Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
|
WO2004011027A1
(fr)
*
|
2002-07-30 |
2004-02-05 |
Baxter International Inc. |
Vaccins multivalents chimeres a conjugue polysaccharidique
|
HUE047780T2
(hu)
|
2002-10-11 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
CN102302776B
(zh)
|
2003-01-30 |
2014-06-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
NZ561879A
(en)
|
2003-03-07 |
2009-05-31 |
Wyeth Corp |
Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
|
NZ546430A
(en)
|
2003-10-02 |
2009-04-30 |
Novartis Vaccines & Diagnostic |
Liquid vaccines for multiple meningococcal serogroups
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
JP2007519746A
(ja)
*
|
2004-01-29 |
2007-07-19 |
バイオシネクサス インコーポレーティッド |
ワクチン調製におけるアミノ−オキシ官能基の使用
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
EP2272531A3
(fr)
|
2004-04-30 |
2011-04-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Intégration du vaccin conjugué de méningococcus
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
US7456000B2
(en)
*
|
2004-08-26 |
2008-11-25 |
Siemens Healthcare Diagnostics Inc. |
Deactivation of linking moieties in antibody-enzyme conjugates
|
BRPI0515516B1
(pt)
|
2004-09-22 |
2017-08-08 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
ES2382048T3
(es)
|
2005-04-08 |
2012-06-04 |
Wyeth Llc |
Composición conjugada de proteína-polisacárido neumococico multivante
|
DK2283857T3
(da)
|
2005-06-27 |
2019-10-28 |
Glaxosmithkline Biologicals Sa |
Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
TWI465248B
(zh)
|
2005-12-22 |
2014-12-21 |
Glaxosmithkline Biolog Sa |
包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
|
EP1993604B1
(fr)
*
|
2006-03-17 |
2015-12-02 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Procédé de préparation de conjugués immunogéniques multivalents complexes
|
ES2383209T3
(es)
|
2006-03-22 |
2012-06-19 |
Novartis Ag |
Regímenes para la inmunización con conjugados meningococicos
|
EP2476434A1
(fr)
|
2006-03-30 |
2012-07-18 |
GlaxoSmithKline Biologicals S.A. |
Composition immunogène
|
ATE511398T1
(de)
|
2006-09-07 |
2011-06-15 |
Glaxosmithkline Biolog Sa |
Inaktiviertes poliovirus mischimpfstoff
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
MX2009011837A
(es)
|
2007-05-02 |
2010-04-22 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
EA200901578A1
(ru)
|
2007-06-26 |
2010-08-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
EP2185196B1
(fr)
|
2007-08-27 |
2014-06-11 |
Longhorn Vaccines & Diagnostics, LLC |
Compositions immunogènes et procédés
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
AU2009215364B2
(en)
|
2008-02-21 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Meningococcal fHBP polypeptides
|
EP2341929B1
(fr)
|
2008-10-06 |
2017-01-25 |
University Of Chicago |
Compositions et procédés associés aux protéines bactériennes emp
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
SI3281947T1
(sl)
|
2009-04-03 |
2020-07-31 |
The University Of Chicago |
Sestave in metode v zvezi z variantami proteina A (SPA)
|
WO2011127032A1
(fr)
|
2010-04-05 |
2011-10-13 |
University Of Chicago |
Compositions et procédés liés aux anticorps de la protéine a (spa) en tant que amplificateur de la réponse immunitaire
|
WO2010135714A2
(fr)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Méthodes de modulation de l'expression des adipocytes utilisant des compositions de micro-arn
|
US20120135037A1
(en)
|
2009-06-01 |
2012-05-31 |
Mizel Steven B |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
US8568735B2
(en)
|
2009-06-22 |
2013-10-29 |
Wyeth Llc |
Immunogenic compositions of Staphylococcus aureus antigens
|
PE20110065A1
(es)
|
2009-06-22 |
2011-01-31 |
Wyeth Llc |
Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
|
WO2011017101A2
(fr)
|
2009-07-27 |
2011-02-10 |
Fina Biosolutions, Llc |
Procédé de production de vaccins à protéine-carbohydrate à niveau réduit de carbohydrate libre
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
BR112012004275A2
(pt)
|
2009-08-27 |
2016-11-16 |
Novartis Ag |
polipeptídios híbridos incluindo sequências meningocócicas de fhbp
|
WO2011036560A2
(fr)
|
2009-09-23 |
2011-03-31 |
Novartis Ag |
Compositions de glycoconjugués et méthodes pour le traitement du vih
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
CN102917730A
(zh)
|
2009-10-27 |
2013-02-06 |
诺华有限公司 |
修饰的脑膜炎球菌fHBP多肽
|
MX2012006961A
(es)
|
2009-12-17 |
2012-10-03 |
Fina Biosolutions Llc |
Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
ES2743156T3
(es)
|
2010-04-23 |
2020-02-18 |
Serum Institute Of India Pvt Ltd |
Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
|
EP2588120B1
(fr)
|
2010-07-02 |
2017-11-15 |
The University of Chicago |
Compositions et méthodes associées à des variants de protéine a (spa)
|
WO2012034067A1
(fr)
|
2010-09-09 |
2012-03-15 |
The University Of Chicago |
Procédés et compositions impliquant des antigènes staphylococciques protecteurs
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
US9493517B2
(en)
|
2011-11-07 |
2016-11-15 |
Glaxosmithkline Biologicals Sa |
Conjugates comprising an antigen and a carrier molecule
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
ES2806945T3
(es)
|
2012-04-26 |
2021-02-19 |
Univ Chicago |
Antígenos de coagulasa estafilocócica y métodos para su uso
|
CA2886938A1
(fr)
|
2012-10-12 |
2014-04-17 |
Glaxosmithkline Biologicals S.A. |
Antigenes de pertussis acellulaires non reticules pour leur utilisation dans des vaccins combines
|
JP2016501550A
(ja)
|
2012-12-27 |
2016-01-21 |
グリコヴァキシン アーゲー |
Crm197に関する方法及び組成物
|
MX362793B
(es)
|
2013-03-08 |
2019-02-13 |
Janssen Vaccines & Prevention Bv |
Vacuna acelular contra pertussis.
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
KR102199096B1
(ko)
|
2013-09-08 |
2021-01-06 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
WO2015052684A2
(fr)
*
|
2013-10-11 |
2015-04-16 |
Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. |
Conjugués polysaccharide-protéine ayant une immunogénicité accrue et leur procédé de production rapide à haut rendement
|
WO2015095868A1
(fr)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Méthodes et compositions permettant d'augmenter les taux d'anticorps protecteurs induits par des vaccins antipneumococciques polyosidiques
|
NZ760783A
(en)
|
2014-01-21 |
2023-07-28 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR20210032013A
(ko)
|
2014-01-21 |
2021-03-23 |
화이자 인코포레이티드 |
스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
AU2015210674B2
(en)
|
2014-01-31 |
2017-08-24 |
Fina Biosolutions, Llc |
Expression and purification of CRM197 and related proteins
|
LT3110442T
(lt)
|
2014-02-28 |
2020-12-28 |
Glaxosmithkline Biologicals Sa |
Modifikuoti meningokokinio fhbp polipeptidai
|
EP2921856B1
(fr)
|
2014-03-18 |
2016-09-14 |
Serum Institute Of India Private Limited |
Analyse quantitative pour de la 4-pyrrolidinopyridine (4-ppy) dans des vaccins conjugués polyssacharide-protéine
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
BE1023004A1
(fr)
|
2014-12-10 |
2016-10-31 |
Glaxosmithkline Biologicals Sa |
Procede de traitement
|
EP3034516A1
(fr)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification de polysaccharides capsulaires de streptocoques
|
IL252915B2
(en)
|
2015-01-15 |
2024-04-01 |
Pfizer |
Immunogenic preparations for use in pneumococcal vaccines
|
JP2018511655A
(ja)
|
2015-03-20 |
2018-04-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
|
AU2016258284C1
(en)
|
2015-05-04 |
2020-09-03 |
Pfizer Inc. |
Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
JP6808658B2
(ja)
|
2015-06-23 |
2021-01-06 |
バイオロジカル イー リミテッド |
多価肺炎球菌コンジュゲートワクチン
|
AU2016295566B2
(en)
|
2015-07-21 |
2019-06-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3377098A1
(fr)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
US11191822B2
(en)
|
2016-06-22 |
2021-12-07 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(fr)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition de conjugués de polysaccharide-protéine pneumococcique
|
TWI789357B
(zh)
|
2016-08-05 |
2023-01-11 |
南韓商Sk生物科技股份有限公司 |
多價肺炎球菌多醣-蛋白質共軛物組成物(二)
|
JP7001686B2
(ja)
|
2016-08-05 |
2022-02-04 |
サノフィ パスツール インコーポレイティッド |
多価肺炎球菌多糖体-タンパク質コンジュゲート組成物
|
JP7104027B2
(ja)
|
2016-09-02 |
2022-07-20 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
淋菌に対するワクチン
|
WO2018048141A1
(fr)
*
|
2016-09-06 |
2018-03-15 |
주식회사 엘지화학 |
Composition comprenant une protéine multivalent de transport de polysaccharide capsulaire et son utilisation
|
CA3037056A1
(fr)
|
2016-09-30 |
2018-04-05 |
Biological E Limited |
Compositions de vaccin antipneumococcique multivalent comprenant des conjugues polysaccharide-proteine
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
BE1025162B9
(fr)
|
2016-12-06 |
2019-01-07 |
Glaxosmithkline Biologicals Sa |
Procede de purification pour les polysaccharides capsulaires
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
EP3576759A4
(fr)
|
2017-01-31 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Procédés de production de conjugués protéine-polysaccharide capsulaire à partir du sérotype 19f de streptococcus pneumoniae
|
CA3051801A1
(fr)
|
2017-01-31 |
2018-08-09 |
Pfizer Inc. |
Compositions de neisseria meningitidis et methodes associees
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
CN111093650B
(zh)
|
2017-09-07 |
2024-03-01 |
默沙东有限责任公司 |
肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
|
NZ765694A
(en)
|
2017-12-06 |
2024-03-22 |
Merck Sharp & Dohme Llc |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
WO2020016322A1
(fr)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Procédés de préparation de polysaccharides séchés
|
EP3607967A1
(fr)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Polypeptides modifiés du méningocoque fhbp
|
EP3894431A2
(fr)
|
2018-12-12 |
2021-10-20 |
GlaxoSmithKline Biologicals SA |
Protéines porteuses modifiées pour glycosylation à liaison o
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
US20220296695A1
(en)
|
2018-12-19 |
2022-09-22 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
WO2020165711A1
(fr)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
COMPOSITIONS DE NEISSERIA MENINGITIDIS<i /> ET PROCÉDÉS ASSOCIÉES
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3136278A1
(fr)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues, kits les comprenant et leurs utilisations
|
WO2020229964A1
(fr)
|
2019-05-10 |
2020-11-19 |
Glaxosmithkline Biologicals Sa |
Production de conjugués
|
EP3757217A1
(fr)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Procédés de purification de protéines
|
EP4003410A1
(fr)
|
2019-07-31 |
2022-06-01 |
Sanofi Pasteur, Inc. |
Compositions de conjugués de polysaccharide-protéine pneumococcique multivalents leurs méthodes d'utilisation
|
EP3777884A1
(fr)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Composition immunogène
|
EP4034157A1
(fr)
|
2019-09-27 |
2022-08-03 |
Pfizer Inc. |
Compositions de neisseria meningitidis et méthodes associées
|
EP3799884A1
(fr)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions immunogènes
|
JP2023503086A
(ja)
|
2019-11-22 |
2023-01-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
細菌サッカリド複合糖質ワクチンの用法及び用量
|
US20230085173A1
(en)
|
2020-02-21 |
2023-03-16 |
Pfizer Inc. |
Purification of saccharides
|
WO2021176409A1
(fr)
|
2020-03-05 |
2021-09-10 |
Sanofi Healthcare India Private Limited |
Combinaison de conservateurs pour composition de vaccin
|
EP3900739A1
(fr)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
|
EP3919076A1
(fr)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
|
BR112022023261A2
(pt)
|
2020-06-12 |
2022-12-27 |
Glaxosmithkline Biologicals Sa |
Imunização bacteriana usando vacina de nanopartícula
|
EP4171624A1
(fr)
|
2020-06-25 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Protéines d'exotoxine a modifiées
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
JP2023538736A
(ja)
|
2020-08-26 |
2023-09-11 |
ファイザー・インク |
B群レンサ球菌多糖-タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
|
WO2022058945A1
(fr)
|
2020-09-17 |
2022-03-24 |
Janssen Pharmaceuticals, Inc. |
Compositions de vaccin multivalentes et leurs utilisations
|
EP4234572A1
(fr)
|
2020-10-20 |
2023-08-30 |
Shanghai Reinovax Biologics Co., Ltd |
Conjugué de protéoglycane et son application
|
EP4232593A1
(fr)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Procédés de purification de polysaccharides bactériens
|
WO2022097010A1
(fr)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
|
WO2023111826A1
(fr)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
|
WO2023118033A1
(fr)
|
2021-12-22 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Vaccin
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
CN114965784B
(zh)
*
|
2022-06-01 |
2023-10-27 |
艾美探索者生命科学研发有限公司 |
多糖活化度的测定方法
|